Eliglustat for Gaucher disease type 1 (GDI): Safety results from a Phase 2 study after 2 years of treatment

Authors
Category Primary study
JournalMolecular Genetics and Metabolism
Year 2011
This article has no abstract
Epistemonikos ID: f5ad005ce1cc60498d6db3c7583c9f4700f6e675
First added on: Feb 04, 2025